Quarterly report [Sections 13 or 15(d)]

Note 9 - Accrued Liabilities

v3.26.3
Note 9 - Accrued Liabilities
9 Months Ended
Sep. 30, 2026
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

9.         Accrued Liabilities

 

Accrued liabilities consisted of the following (in thousands):

 

   

September 30, 2026

   

December 31, 2025

 

Clinical trial costs

  $ 2,812     $ 1,291  

Compensation

    1,534       1,380  

Professional services fees

    171       120  

Research and development services

    168       749  

Other

    6       5  

Total accrued liabilities

  $ 4,691     $ 3,545